Kutz, what is your analysis on the new trial announcement........I have been in and out for years............
Elan and Wyeth to initiate Phase 3 clinical trial of Bapineuzumab in Alzheimer's disease Co and Wyeth (WYE) announce the decision to initiate a Phase 3 clinical program of their lead immunotherapeutic candidate, Bapineuzumab, for the treatment of patients with mild to moderate Alzheimer's Disease. This decision was based on the seriousness of the disease and the totality of what the companies have learned from their immunotherapy programs, including a scheduled Interim look at data from an ongoing Phase 2 study, which remains blinded. Phase 3 clinical trial design will be finalized with regulatory agencies, and subject to regulatory approval, it is intended for the trial to begin in 2H07.
trader